atai Life Sciences (ATAI)
(Real Time Quote from BATS)
$1.91 USD
+0.07 (3.80%)
Updated Apr 26, 2024 02:08 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
ATAI 1.91 +0.07(3.80%)
Will ATAI be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ATAI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ATAI
Are You Looking for a Top Momentum Pick? Why atai Life Sciences N.V. (ATAI) is a Great Choice
Is Align Technology (ALGN) Stock Outpacing Its Medical Peers This Year?
ATAI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aveanna Healthcare (AVAH) Reports Q4 Loss, Tops Revenue Estimates
LifeStance Health Group (LFST) Reports Q4 Loss, Tops Revenue Estimates
Elevance Health (ELV) & Verizon Partner to Bring Health Equity
Other News for ATAI
Here's What You Missed in Cannabis, Psychedelics This Week
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
Atai Life announces dosing of first patient in Phase 2a study of BPL-003
Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
Jim Cramer Slams Political Blocking Of 'LSD-Derived Antidepressants,' Citing Strong Test Data 'Showing They Worked'